Boston, MA 04/08/2014 (wallstreetpr) – IsoRay, Inc. (NYSEMKT: ISR) on reaching the apex of success, made up to an astonishing news that prostate implant can cure human cancer. This is the first time in medical history that with such impressive determination and perseverance, a company has made such a sensational discovery. IsoRay is a medical-technology company, which deals with various cancer treatments like prostate cancer, brain cancer, lung cancer, head and neck cancer.
On the way with the discovery:
The technology used by IsoRay, Inc. (NYSEMKT: ISR), showed positive index in medical market. Human prostate can be implanted by using Cesium-131 seeds along with C4 Imaging’s system. This ground-breaking discovery has opened a broad gateway for future cancer treatment. Usually, in this treatment process doctors apply small dosage of radiation on the removed tumor portion where there is a possibility of cancerous cells.
Directorial statement on the issue:
The CEO of IsoRay, Dwight Babcock has revealed the truth behind the scenario. The team of researchers and doctors struggled day and night to discover such an amazing method. The ‘Cesium-131 seeds’ combined with ‘C4 Imagining’s system’ are the backbone to combat prostate cancer.
These latest technologies applied together can give a better outcome in the future. The ongoing research work in the company and in collaboration with various other medical companies indeed has a clear idea on the usefulness of Cesium-131.
Company on share market position:
IsoRay, Inc. (NYSEMKT: ISR)’s share value leaped to 12.9% after the company revealed the story of Cesium-131 as an essential way to fight human prostate cancer. Steven Frank, the hand behind the first human prostate implant from Anderson Cancer Center, stated that the Cesium-131 offers the acute remedy for the issue.
The amazing invention is believed to turn the medical configuration very shortly. The company, with this outstanding revolutionary discovery can reach up to a huge prospective level in the investment market.
